公开(公告)号：US20050043408A1

公开(公告)日：2005-02-24

申请号：US10492553

申请日：2002-10-15

申请人： Faustinus Yeboah ,  Yasuo Konishi ,  Sung Cho ,  Jittiwud Lertvorachon ,  Taira Kiyota ,  Popek Tomasz

发明人： Faustinus Yeboah ,  Yasuo Konishi ,  Sung Cho ,  Jittiwud Lertvorachon ,  Taira Kiyota ,  Popek Tomasz

IPC分类号： A61K31/00 ,  A61K31/04 ,  A61K31/137 ,  A61K31/195 ,  A61K31/222 ,  A61K31/345 ,  A61K31/352 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/47 ,  A61K31/65 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P25/02 ,  C07C219/30 ,  C07C31/137

CPC分类号： A61K31/47 ,  A61K31/00 ,  A61K31/04 ,  A61K31/137 ,  A61K31/195 ,  A61K31/222 ,  A61K31/345 ,  A61K31/352 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/65 ,  C07C219/30

摘要： The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

摘要翻译： 本发明提供了通过高通量筛选测定从化合物文库鉴定的蛋白质糖基化的新抑制剂。 如此确定的抗糖化剂的特征在于各种化学结构，并且可用于预防或治疗年龄，糖尿病和吸烟相关并发症，包括神经病，肾病，眼病理或机械性能的丧失 的胶原组织。 鉴定为具有抗糖基化活性的化合物是特别有用的肾上腺素及其类似物，特别是D-肾上腺素及其类似物，其特别可用于预防或治疗年龄，糖尿病和吸烟相关眼 病态。

公开(公告)号：US20080139664A1

公开(公告)日：2008-06-12

申请号：US12029209

申请日：2008-02-11

申请人： Faustinus YEBOAH ,  Yasuo KONISHI ,  Sung Ju CHO ,  Jittiwud LERTVORACHON ,  Taira KIYOTA ,  Tomasz Popek

发明人： Faustinus YEBOAH ,  Yasuo KONISHI ,  Sung Ju CHO ,  Jittiwud LERTVORACHON ,  Taira KIYOTA ,  Tomasz Popek

IPC分类号： A61K31/135 ,  A61P3/00

CPC分类号： A61K31/47 ,  A61K31/00 ,  A61K31/04 ,  A61K31/137 ,  A61K31/195 ,  A61K31/222 ,  A61K31/345 ,  A61K31/352 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/65 ,  C07C219/30

摘要： The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

摘要翻译： 本发明提供了通过高通量筛选测定从化合物文库鉴定的蛋白质糖基化的新抑制剂。 如此确定的抗糖化剂的特征在于各种化学结构，并且可用于预防或治疗年龄，糖尿病和吸烟相关并发症，包括神经病，肾病，眼病变或机械性能的丧失 的胶原组织。 鉴定为具有抗糖基化活性的化合物是特别有用的肾上腺素及其类似物，特别是D-肾上腺素及其类似物，其特别可用于预防或治疗年龄，糖尿病和吸烟相关眼 病态。